Skip to main content
Premium Trial:

Request an Annual Quote

The Bloggers Retort

Premium

This month, bloggers respond to a number of issues: shaky peer-review, condemned geneticists, GINA, and even electronic notebooks.

Demanding Answers

Out on the Web, people are still wondering what was going on at the journal Proteomics to have Mohamad Warda and Jin Han's paper, entitled "Mitochondria, the missing link between body and soul: Proteomic prospective evidence," slip through the peer-review process. Though the paper was retracted — citing plagiarism as the reason — bloggers PZ Myers, Stephen Salzberg, Attila Csordás, and Lars Juhl Jensen find that inadequate. "The plagiarism is bad all right, but my main concern was that such a blatantly goofy paper made it through peer review. How?" writes Myers. The bloggers are awaiting an explanation from editor-in-chief Michael Dunn.

http://scienceblogs.com/pharyngula
http://genefinding.blogspot.com
http://larsjuhljensen.wordpress.com
http://pimm.wordpress.com

Listing Sins

Not only has the Vatican come up with new deadly sins that include genetic experimentation, bloggers have come up with their own set of deadly sins. Sciencebase's David Bradley made a list of deadly sins for scientists which includes plagiarism (and self-plagiarism), lying, vanity, and procrastination. Eye on DNA's Hsien-Hsien Lei focused her list on the deadly sins of genetics, including: believing that genes are deterministic, eugenics, fabricating results, and blogging about DNA. Bradley's readers also add working grad students too hard, inflating budget proposals, being a "smarty-pants," and having "delusions of competency" to the list.

http://www.eyeondna.com
http://www.sciencebase.com/science-blog

Notebooks Minus the Paper

Derek Lowe and PhilipJ are impressed by digital lab notebooks. At In the Pipeline, Lowe writes that he can easily draw chemical structures and search for specific data, and at Biocurious, PhilipJ likes their ability to store digital images and bits of code — as well as being much more legible. At Omics! Omics!, Neil Saunders has a related post on how to think about data. If scientists can structure their data generically and coherently, he says, that will make using electronic notebooks a breeze.

http://pipeline.corante.com
http://biocurious.com
http://nsaunders.wordpress.com

Need Protection?

The Genetic Information Nondiscrimination Act may have passed the US House of Representatives, but it's not yet law. Genetic Future's Daniel MacArthur blogs about what he considers a well-reasoned opposition opinion to the bill: that better information will lead to better management of risk. Texas, meanwhile, passed a new law that Jere Odell of PredictER says might make GINA more germane — the law requires that insurance companies give employees' health records to their employers. Odell points out that local media outlets in Texas are reporting that genetic test results are already protected, leading him to wonder what difference GINA will make.

http://www.genetic-future.com
http://predicter.blogspot.com

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.